Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].
Znoyko OO, Klimova EA, Maevskaya MV, Shuldyakov АA, Linkova YN, Morozova MA. Znoyko OO, et al. Ter Arkh. 2016;88(11):156-162. doi: 10.17116/terarkh20168811156-162. Ter Arkh. 2016. PMID: 28635836 Review. Russian.
[Infections, pandemics and sleep disorders].
Kolokolov OV, Salina EA, Yudina VV, Shuldyakov AA, Runnova AE. Kolokolov OV, et al. Among authors: shuldyakov aa. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(4. Vyp. 2):68-74. doi: 10.17116/jnevro202112104268. Zh Nevrol Psikhiatr Im S S Korsakova. 2021. PMID: 34078863 Russian.
Infections, Pandemics, and Sleep Disorders.
Kolokolov OV, Salina EA, Yudina VV, Shuldyakov AA, Runnova AE. Kolokolov OV, et al. Among authors: shuldyakov aa. Neurosci Behav Physiol. 2022;52(3):319-325. doi: 10.1007/s11055-022-01242-2. Epub 2022 Jun 7. Neurosci Behav Physiol. 2022. PMID: 35692961 Free PMC article.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
17 results